Antitumor Effects of RHAMM-Target Peptides on Prostate Tumor Xenografts in Nude Mice

Download Citation in txt Download Citation in bib Download Citation in ris

Author Info

Natalia Akentieva

Corresponding Author

Natalia Akentieva
Institute of Problems of Chemical Physics RAS, Moscow Region, Chernogolovka, Russia

A B S T R A C T

Prostate cancer is a high incidence disease in men and a major cause of cancer deaths. RHAMM-target peptides used for treatments of prostate tumors. Peptides were added to the PC3mLN4 cells (GEGEEGEE, DFGEEAEE and RYQLHPYR, final concentration 40 μg / ml, dose for inoculating the mouse 2.5 mg / kg). 45 nude mice were injected with 0.1 ml of PC3mLN4 cell suspension of 2 × 107 cells/ml subcutaneously. The nude mice models were randomly divided into five groups of 8 in each group. The standard models in mice were judged by 100% tumor grafting. The results showed that GEGEEGEE peptide inhibited tumor growth by 58%, DFGEEAEE peptide inhibited tumor growth by 63.5%, but RYQLHPYR peptide significantly inhibited of tumor growth by 94.6%. These results have demonstrated that RHAMM-target peptides have a therapeutic potential for the treatment of cancer.

Article Info

Article Type

Research Article

Publication history

Received: Thu 07, May 2020
Accepted: Sat 06, Jun 2020
Published: Wed 17, Jun 2020

Copyright

© 2023 Natalia Akentieva. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.
DOI: 10.31487/j.CJSO.2020.01.01